adrenal venous sampling
ProcedurePatients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
NCT Number: NCT06192238
This multicenter study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of adrenal venous sampling (AVS) via antecubital and femoral approach for patients with primary aldosteronism. The consistency of AVS with pathological results and clinical outcomes, the factors affecting the success of AVS, and the optimal population for AVS will be aslo analyzed in this study.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Observational
Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account for 95% to 98% of PA. Subtype diagnosis is crucial for the treatment of primary aldosteronism, which conducts the appropriate treatment strategy. Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. How to improve the success rate of AVS has been a hot topic in the field of primary aldosteronism. This multicenter registry study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of AVS via antecubital and femoral approach for patients with primary aldosteronism. The consistency of AVS with pathological results and clinical outcomes, the factors affecting the success of AVS, and the optimal population for AVS will be also analyzed in this study.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Time frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
Time frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
Time frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
Time frame: At AVS procedure
Types of catheter at the time of Adrenal Venous Sampling via antecubital approach or femoral approach
Time frame: At AVS procedure
Time of the procedure
Time frame: At AVS procedure
Time of fluoroscopy
Time frame: At AVS procedure
The contrast agent dosage
Time frame: 1 week after AVS procedure
Complications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)
Time frame: At AVS procedure
the cost of the procedure
Time frame: 1 week After AVS procedure
Pathological types of primary aldosteronism(to compare the consistency between adrenal venous sampling results and histopathological results if the patients underwent adrenalectomy.)
Contact information is provided by the study sponsor or research team.
Hui Dong, MD
CONTACT
Xiongjing Jiang, MD
CONTACT
Chinese Academy of Medical Sciences, Fuwai Hospital
Other
A National Multicenter Study of Adrenal Venous Sampling for the Subtype Diagnosis of Primary Aldosteronism in China
Acronym: CNAVS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06246357
Adenoma, Adrenal Gland Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02751021
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Caen, Normandy, France
View Trial DetailsNCT04605549
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Greenbrae, California, United States
View Trial DetailsNCT07328230
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Beijing, Beijing Municipality, China
View Trial Details